Latest Content

Toric, spheric, and multifocal contact lenses are 86%, 79%, and 29% more profitable, respectively, than equivalent glasses-only patients.

Glaukos finishes US pivotal enrollment for Preserflo MicroShunt, targeting advanced glaucoma after failed surgeries, with 12‑month IOP reduction data guiding FDA plans.

The trial will enroll approximately 111 patients across the US and Europe following positive FDA feedback from a Type D meeting

Jade Coats, OD, FAAO, stated that providing pre- and post-op patient care can provide an opportunity to support ophthalmologists.

Through at home delivery, and in-office dispense in permitted states, Orasis Pharmaceuticals and BlinkRx aim to improve accessibility of Qlosi eye drops for presbyopia treatment.

Protecting eye health today requires more than regular eye exams and good lighting

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the US.

Michael Ip, MD, presented a large-scale analysis of OCT biomarkers in diabetic macular edema (DME), drawing on data from the DRCR Retina Network's Protocol T trial.

The FDA confirmed phase 1 and nonclinical data support pediatric phase 2 development of IVMED-85, a non-atropine daily eye drop for myopia progression.

Frantz EyeCare reported 98% of Light Adjustable Lens patients within ±0.50 D of target but omitted cohort, follow-up, and safety details.

i-Lumen Scientific randomly assigned its first US patient in the sham-controlled i-SIGHT2 pivotal study of its investigational, noninvasive bioelectric AMD device at Texas Retina Associates.

A 10-year analysis finds latanoprost accounts for 40% of glaucoma prescriptions in New Zealand.

Jessica Steen, OD, FAAO, DipABO, stated that each ADC can have distinct ophthalmic monitoring needs and management protocols.